Doctor in Industrial Economics, Jinan University and Master in Monetary Banking, Xiamen University.
20 years of experience in Investment & Financing, Merger & Acquisition, Industrial Integration and Corporate Management.
Experience includes Vice President of Shenzhen Capital Group, Deputy General Manager of Shenzhen Airport Group and leader of several international mergers, Managing Director of Shenzhen HTI Group, Manager of the Department of Investment of E Funds Management and Director of China Southern Asset Management.
Serves as the Vice Chairman of Shenzhen Venture Capital Association, Executive Vice President of Shenzhen Science and Technology Entrepreneur Promotion Association and Part-time Professor of Southwestern University of Finance and Economics, Shenzhen Audencia Business School, Xidian University and China University of Mining and Technology.
Publications include Research on the Behavior and its Market Effect of Securities-Investing Funds in China and The Management and Operation of Investment Banks throughout the World.
Select Investment Cases include Mob.com (002174), Jiangsu Acetec Semiconductor (002077), Transwap Technology, Akeso Biopharma, Fapon Biotech, ImmunoVir, Inda Biotechnology and Chengdu Shuangliu International Airport, etc.
CEO, Managing Partner
BA from the accounting department of Ocean University of China.
Has depth financial and tax professional background with a focus on risk control in the investment field.
Worked in several leading state-owned enterprises such as Cosco and Aerospace Science and Technology in China. He is responsible for auditing, accounting, financial management, financial analysis and contract auditing.
MBA from University of Central Lancashire.
Started to engage in venture capital investment in 2001. 14 years of working experience in Shenzhen Capital Group. He was the General Manager of Shenzhen Capital Group Guaranty Corporation.
Over 10 companies he invested before have successfully completed IPO process or were purchased by other listed companies. Select investment cases include Kugou Music (merged by Tencent), NetDragon Websoft (listed in Hong Kong), 91assistant (merged by Baidu), 7road.com (merged by changyou.com), 99Wuxian（ listed in Australia）, Dongguan Kingsun Optoelectronic (listed on Shenzhen SME Board), Handpay（ merged by Heilan ）, etc.
Lanzhou University MBA, graduated from the College of Life Sciences, Xiamen University.
Sixteen years of experience in a range of biomedical research fields including monoclonal antibody and vaccine development, GMP production and clinical trial management.
Lead the world's first hepatitis E vaccine through GMP production.Years of experience in biomedical research and development, production management, and large pharmaceutical management.
More than 5 years of experience in industrial investment and financing, familiar with capital markets and listed company management.
Chief of Parmaceutical Sector in Jiangsu-Zhejiang-Shanghai .Postgraduate in Biochemistry and Molecular Biology, Xiamen University.
Employment experience includes Roche R&D Center in Shanghai where he was responsible for development of therapeutic antibodies.
Has considerable industrial experience and participated in the formation of several companies including Huading, Sunda Science & Tech and Jiaai Medical, etc.